Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Tunisia has been steadily growing over the past few years, with a significant increase in demand for these drugs.
Customer preferences: Tunisian customers are increasingly becoming aware of the importance of anti-coagulants in preventing blood clots, stroke, and other cardiovascular diseases. As a result, there has been a growing demand for these drugs, particularly among the elderly population. Patients with atrial fibrillation, deep vein thrombosis, and pulmonary embolism are the primary consumers of anti-coagulants.
Trends in the market: One of the significant trends in the Tunisian Anti-Coagulants market is the shift from traditional anti-coagulants to newer oral anticoagulants (NOACs). NOACs are more convenient and effective than traditional anti-coagulants, which require regular monitoring and dosage adjustments. The increased adoption of NOACs is expected to drive the growth of the Anti-Coagulants market in Tunisia. Additionally, there has been an increase in the number of pharmaceutical companies entering the Tunisian market, leading to increased competition and better access to drugs for patients.
Local special circumstances: Tunisia has a high prevalence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market. Additionally, the country has a rapidly aging population, which is more susceptible to cardiovascular diseases. The government has also taken steps to improve access to healthcare, including the provision of free healthcare for elderly citizens.
Underlying macroeconomic factors: The Tunisian economy has been growing steadily, with a focus on developing the healthcare sector. The government has invested in improving healthcare infrastructure, including the construction of new hospitals and clinics. Additionally, the country has a well-established pharmaceutical industry, which has contributed to the growth of the Anti-Coagulants market. The government has also implemented policies to encourage foreign investment in the healthcare sector, leading to increased competition and better access to drugs for patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
